Source: DGNews  |  Posted 8 years ago

MONT SAINT-HILAIRE, QC -- March 17, 2003 -- Axcan Pharma Inc. ("Axcan" or the "Company") announced today that it received approval from the Therapeutic Products Directorate of Health Canada for Helcide, a patented single capsule triple therapy, for the eradication of Helicobacter pylori which is a bacterium now recognized as being the main cause of gastric and duodenal ulcers. Each Helcide capsule contains the equivalent of 40 mg of bismuth biskalcitrate (bismuth), 125 mg of metronidazole and 125 mg of tetracycline hydrochloride (tetracycline), and is administered in combination with a proton pump inhibitor.

"We are very pleased with this approval since our studies confirmed that Helcide is not only as effective as the most widely prescribed therapeutic regimen for the eradication of Helicobacter pylori, but it can be administered successfully in patients who are resistant to existing therapies," indicated Dr. Fran